ASCO GU 2023: Talazoparib Improves Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The PARP inhibitor appears effective regardless of homologous recombination repair status
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.